Abstract
Background Legalization of cannabis for medical uses has proceeded without well-controlled studies. Real world patterns of medical cannabis use are highly variable and rarely overseen by a physician. Smartphone assessments that capture ecologically valid patterns of medical cannabis use and health symptoms may help clarify risks and benefits.
Methods As part of a larger, randomized trial (NCT03224468), adults (N=181) seeking cannabis for insomnia, pain, or anxiety or depressive symptoms were randomized to obtain a medical cannabis card immediately (MCC) or to a waitlist control (WLC) and completed 12-weeks of daily web-based surveys on cannabis use and three health outcomes: sleep, pain, and depressive symptoms.
Results Completion rates in this long-term, daily survey design were high (median completed assessments: 72 out of 90 days). Daily reports of cannabis use were consistent with monthly interview assessments and urinalysis. The MCC group increased cannabis use frequency following randomization, while WLC did not. Within the MCC group, self-reported sleep quality was significantly higher on cannabis use days, compared to nonuse days. The MCC group displayed long-term sleep improvements, paralleled by increased cannabis frequency. Daily associations between cannabis use and self-reported pain or depressive symptoms were not significant.
Conclusion Cannabis use is associated with same day improvements in self-reported sleep quality, but not pain or depressive symptoms, although sleep improvements occurred within the context of potentially risky increases in use. Long-term, web-based assessments of cannabis appear valid and feasible, providing a robust method for future real-world effectiveness studies with expanded and objective measures.
Funding/Support This work was funded by R01DA042043; PI: JMG.
Competing Interest Statement
AEE has served as a consultant to Charles River Analytics (NIDA SBIR grant) and Karuna Pharmaceuticals (Chair Data Monitoring Board). BTC has equity holdings in Abbot Laboratories, Gilead Sciences Inc., Medtronic PLC, Pfizer Inc., Thermo Fisher Scientific, Varian Medical Systems Inc., and Waters Corporation. GNP has equity holdings in Pfizer Inc. Other authors report no potential conflicts.
Clinical Trial
NCT03224468
Funding Statement
This study was funded by NIH R01DA042043
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Research Committee of Mass General Brigham (formerly Partners HealthCare) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Submitted version
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
